度洛西汀治疗抑郁症及广泛性焦虑障碍临床应用指导建议

Clinical therapeutic recommendation on duloxtine in treatment of major depressive disorder and generalized anxiety disorder

抑郁症及广泛性焦虑障碍都是常见的负性情绪障碍,具有患病率高、复发率高、致残率高的特点,目前倡导全病程治疗。新型抗抑郁药均能治疗抑郁症及广泛性焦虑障碍,度洛西汀作为5-羟色胺与去甲肾上腺素再摄取抑制剂类抗抑郁药物的一种,有大量临床证据表明,其在抗抑郁、抗焦虑治疗方面具有起效快、临床治愈率高及安全性好、不良反应少等特点。本文重点介绍近年来国内外在度洛西汀临床应用中的治疗学和循证医学研究进展,结合广大专家的用药经验,为临床医生提供更客观、更规范的治疗选择和治疗方案,以进一步改善患者预后,促进患者回归社会。

Depression and generalized anxiety disorder （GAD）, which are considered as common negative mood disorder, are charactered by high rate of prevelance, recurrence, and disability, and should be treated over the course of the whole disease. New antidepressants have high efficiency in the treatment of depression and GAD. Duloxetine, which belongs to the SNRIs, is charactered by fast onset of action, higher cure rate and safety and less adverse reaction. The paper mainly introduced the recent research progress in therapeutics and evidence based medicine of duloxetine in clinical practice, and also provided the more objective and standard treatment projects combined with expert experience, in order to improve the prognosis of patient and promote the patient to return to society.